In CKD patients, a stepped increase in hypertension and dyslipidaemia prevalence, lipid-lowering therapy, and increasing levels of glucose, insulin, HOMA-IR, triglycerides, and 24-h urinary protein excretion were observed with worsening kidney function (p < 0.05 for all) whereas no changes were seen in other lipid parameters. This evidence concerns the gene INS and chronic kidney disease.